Drugs / REGN3470-3471-3479
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02777151 | May 2016 → Apr 2017 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT03576690 | — | Ebola hemorrhagic fever | Regeneron Pharmaceuticals | Available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN3470-3471-3479 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03576690 ↗ |
| Modality | Monoclonal antibody | “co-formulated cocktail of three human monoclonal antibodies” PMID 29929783 ↗ Jun 2018 |
| Route | Intravenous | “receive a single intravenous dose of REGN3470-3471-3479 or placebo on day 1 (baseline)” PMID 29929783 ↗ Jun 2018 |